Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range

Sales of $10.1 billion driven by strong underlying base business performance Reported sales decreased 2.6 percent due to anticipated decline in COVID-19 testing-related sales versus prior...

Related Keywords

China ,Robertb Ford , ,Core Laboratory ,Cardiovascular Systems Inc ,Abxience Holdings ,Linkedin ,Acelis Connected Health ,European Union Medical Device Regulations ,European Union ,Abbott Laboratories ,Facebook ,European Union Medical Device ,Bigfoot Biomedical ,Cardiovascular Systems ,Nine Months ,Pediatric Nutrition ,Adult Nutrition ,Rapid Diagnostics ,Heart Failure ,Emerging Markets ,Medical Devices ,Diabetes Care ,Structural Heart ,Freestyle Libre ,Aristocrats Index ,Investor Relations ,Private Securities Litigation Reform Act ,Annual Report ,Consolidated Statement ,Quarter Ended September ,Operating Cost ,Specified Items ,Common Share ,Common Shares ,Diluted Earnings ,Months Ended September ,Nine Months Ended September ,Medical Device Regulations ,Vitro Diagnostics Medical Device Regulations ,Medical Device ,Vitro Diagnostics Medical Device ,Gross Margin ,Markets ,